Navigation Links
AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
Date:9/1/2009

QUEBEC CITY, Sept. 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, M.D., will present a corporate overview at the upcoming Rodman Renshaw Annual Global Investment Conference on Wednesday, September 9, 2009 at 12:30 p.m. (eastern time) in the Spellman Salon (5th floor) of the New York Palace Hotel in New York City.

A live webcast of the presentation will be available on AEterna Zentaris' website at www.aezsinc.com in the Investors section. A replay will also be available for a period of 30 days on the Company's website.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
4. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
5. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
6. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
7. AEterna Zentaris Receives US$10 Million from Institutional Investors
8. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
9. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
11. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Switzerland (PRWEB) , ... January ... ... provider of advanced software solutions for pharmaceutical research and development (R&D), today ... expertise in omic data analysis and interpretation for the rapidly evolving field ...
(Date:1/19/2017)... Jan. 19, 2017  ArmaGen, Inc., today announced ... Ph.D., as chief executive officer, as well as ... brings to ArmaGen more than 17 years of ... development of biotherapeutics and pharmaceuticals. ... diverse experience and skillset necessary to lead ArmaGen ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... engineers, and scientists from around the world, was today awarded the "Best Science ... is based entirely on merit and decided upon by a dedicated team of ...
(Date:1/19/2017)... YORK , Jan. 18, 2017 ... to reach USD 92.9 billion by 2025, according ... Inc. Pharmaceutical industry has been adaptive of the ... as early as 2002. Among the services outsourced, ... forerunners. For instance, Johnson & Johnson was the ...
Breaking Biology Technology:
(Date:1/11/2017)... 11, 2017 Intoxalock, a leading ignition interlock ... of its patent-pending calibration device. With this new technology, ... securely upload data logs and process repairs at service ... "Fighting drunk driving through the application of cutting-edge ... large, but also for the customer who can get ...
(Date:1/6/2017)... Jan. 5, 2017  SomaLogic announced today that ... Alliance" established by iCarbonX, the China ... a "Global Digital Health Ecosystem that can define ... of individual,s biological, behavioral and psychological data, the ... the companies, SomaLogic will provide proteomics data and ...
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
Breaking Biology News(10 mins):